Background <p>Although immunotherapy has revolutionized cancer treatment, its efficacy in castration-resistant prostate cancer (CRPC) remains limited, largely due to an immunologically "cold" tumor microenvironment with scarce T-cell infiltration. Unraveling the molecular mechanisms underlying immune evasion and developing novel strategies to activate innate antitumor immunity are therefore critical to overcoming immunotherapy resistance in CRPC.</p> Methods <p>Using bioinformatic approaches, we analyzed the…
Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer
Journal for ImmunoTherapy of Cancer | | Gao, L., Wang, B., Liu, H., Liu, P., Liu, L., Han, J., Wang, X., Dou, B., Sun, F., Liu, W., Wang, X., Feng, T., Zhao, R., Yang, X., Chen, W., Hu, J., Han, B.
Topics: prostate-cancer, skin-cancer, blood-cancer, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer